![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Alfuzosin hydrochloride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2007-031 - Rev 00
This Chemical Type CEP, issued on November 10, 2014, remains in force until August 17, 2016, ensuring its reliability within the pharmaceutical industry.
Substance Number 1287 associated with this CEP further emphasizes